Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Debt to Equity (2016 - 2025)

Haemonetics has reported Debt to Equity over the past 16 years, most recently at $1.34 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 0.51% year-over-year to $1.34; the TTM value through Dec 2025 reached $1.34, down 0.51%, while the annual FY2025 figure was $1.49, 77.32% up from the prior year.
  • Debt to Equity for Q4 2025 was $1.34 at Haemonetics, down from $1.44 in the prior quarter.
  • Over five years, Debt to Equity peaked at $1.49 in Q1 2025 and troughed at $0.84 in Q1 2024.
  • A 5-year average of $1.13 and a median of $1.09 in 2021 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: soared 146.89% in 2022 and later fell 23.96% in 2023.
  • Year by year, Debt to Equity stood at $1.12 in 2021, then fell by 11.59% to $0.99 in 2022, then decreased by 6.6% to $0.92 in 2023, then skyrocketed by 46.35% to $1.35 in 2024, then fell by 0.51% to $1.34 in 2025.
  • Business Quant data shows Debt to Equity for HAE at $1.34 in Q4 2025, $1.44 in Q3 2025, and $1.39 in Q2 2025.